What Xaloptic T Treats: Main Uses and Benefits

Xaloptic T is utilized in a therapeutic context to help manage elevated intraocular pressure (IOP). Maintaining IOP within an appropriate range is a key objective in supporting ocular health.

This medication is primarily indicated for individuals diagnosed with open-angle glaucoma and those with a condition known as ocular hypertension. These conditions are associated with abnormally high pressure inside the eye, which can contribute to potential eye damage.

Its function is to facilitate a reduction in this elevated pressure. This action supports the overall management plan for the condition. The overall goal of using this medication is to assist in preserving the health of the eye's optic structures by addressing the pressure factor.

Xaloptic T is indicated for use in adult patients (including older adults) diagnosed with open-angle glaucoma or ocular hypertension when their intraocular pressure (IOP) is not adequately controlled by a single-agent eye drop. Eligibility is strictly defined by regulatory documents, particularly due to the Timolol (beta-blocker) component.

Contraindicated Populations

Use is absolutely prohibited in patients with:

• Reactive Airway Disease: Including bronchial asthma (current or history of) or severe chronic obstructive pulmonary disease (COPD).
• Cardiac Conditions: Including sinus bradycardia, second or third degree atrioventricular (AV) block (unless paced), overt cardiac failure, or cardiogenic shock.
• Hypersensitivity: Known allergy to latanoprost, timolol, or any other component.

Restricted and Non-Recommended Use

Interactions with other medicines and products

This section details officially documented interaction patterns for Xaloptic T, which is a fixed combination of Latanoprost and Timolol. The interaction profile is structured by both pharmacodynamic (PD) and pharmacokinetic (PK) constraints, resulting in specific co-administration restrictions defined in regulatory documents.

Restrictions on Co-Administration

Clinically Significant Interaction Patterns

Co-administration with agents that share similar systemic effects to Timolol may result in additive effects, leading to potential outcomes such as hypotension or marked bradycardia. These classes include oral beta-adrenergic blocking agents, oral calcium channel blockers, antiarrhythmics, digitalis glycosides, and parasympathomimetics. Furthermore, CYP2D6 inhibitors (e.g., quinidine, fluoxetine, paroxetine) can interfere with the metabolic clearance of the Timolol component, thereby increasing its systemic exposure and potentially potentiating systemic beta-blockade.

Timing-Based Administration Requirements

When co-administering Xaloptic T with any other topical ophthalmic drug product, a minimum separation of at least five minutes is mandated between applications. Soft contact lenses must be removed prior to administration and may be reinserted 15 minutes after the eye drops are instilled.

Xaloptic T operates through a dual-mechanism synergy targeting the two main variables of aqueous humor dynamics: fluid production and fluid drainage. Timolol, the beta-blocker component, functions as a non-selective antagonist on beta1 and beta2 receptors in the ciliary body. This action suppresses the sympathetic signaling that drives fluid secretion, reducing the intracellular concentration of cAMP and thereby decreasing the rate of aqueous humor formation. Concurrently, the Latanoprost component acts via its active metabolite as an agonist on the Prostaglandin F ( FP) receptor. This binding initiates a molecular cascade that causes the relaxation and remodeling of the ciliary muscle and associated connective tissues. This structural change lowers resistance and promotes fluid exit through the uveoscleral outflow pathway. The combination of reduced fluid inflow and enhanced fluid outflow produces a coordinated, additive physiological modulation of intraocular fluid volume.

Official Administration Guidelines for Xaloptic T

Xaloptic T is administered as a topical ophthalmic treatment. Strict adherence to the prescribed dosing is essential, as use exceeding the recommended frequency may reduce the intended therapeutic effect.

Procedural Requirements

To ensure proper application and minimize contamination risk, follow these steps and conditions:

1. Preparation: If using a multi-dose ophthalmic emulsion form, shake the container well just before each use.
2. Contact Lenses: Remove contact lenses prior to administration. Lenses may be reinserted 15 minutes after the medication is administered.
3. Multiple Drops: If more than one topical ophthalmic medication is being used, the drugs must be administered with an interval of at least five (5) minutes between each application.
4. Handling: To prevent contamination that could lead to serious ocular infection, avoid allowing the tip of the dispensing container to contact the eye or surrounding structures.

Research Evidence / Overview of Studies

Phase 3 Clinical Trials: Core Efficacy

Research has examined the potential action of the drug, and studies have evaluated its potential to affect quality of life in participants. Key randomized controlled trials (RCTs) evaluated participant-reported symptom severity and objective clinical markers over periods generally lasting 12 weeks to 2 years.

• Intraocular Pressure (IOP) Reduction: Monotherapy studies explored whether the drug was associated with a reduction in IOP by 22% to 39% over treatment periods of 1 to 12 months. This reduction was generally maintained in studies extending up to 2 years.
• Pain and Inflammation: Studies have examined whether the drug is associated with changes in pain scores and specific inflammatory markers. Findings regarding these secondary markers have varied.
• Long-term Exposure: Long-term exposure was investigated in studies conducted for up to 2 years, focusing on systemic and ocular changes over time.

Combination Therapy Studies

Clinical research has explored the use of the drug in a fixed-dose combination alongside a common standard-of-care medication (Timolol). Studies assessed whether the combination is associated with affecting specific clinical and functional measures when compared to either component used alone.

A meta-analysis was performed on three international Phase 3 studies comparing the combination to monotherapies. These findings were reviewed as part of the total available evidence for managing elevated IOP.

Pharmacoeconomic and Real-World Evidence

Observational studies examined whether the drug's use impacted overall healthcare costs by tracking emergency room visits and hospital stays in large patient cohorts. One area of research was whether the drug was associated with a sustained effect on symptoms when used outside of a strictly controlled clinical trial setting.

• Hospitalization Rates: A large-scale RCT tracked the rate of hospitalizations over a one-year follow-up period and compared these findings to the control group.
• Patient Compliance: Real-world data collection has explored patient adherence and persistence with the prescribed medication regimen.

Key Studies & References Comparative efficacy and safety of the fixed versus unfixed combination of latanoprost and timolol in Chinese patients with open-angle glaucoma or ocular hypertension

Common questions about Xaloptic T (FAQ)

Q: Why did my doctor prescribe Xaloptic T instead of a different medicine?

A: Regulatory guidance and official documents indicate that this combination product is typically prescribed when your intraocular pressure (IOP) has not been adequately controlled by using a single-ingredient eye drop. The combination works in two different ways to lower pressure. Fixed combinations are often noted for their role in potentially simplifying the daily dosing regimen compared to using two separate medications.

Q: Is Xaloptic T the same as regular Xaloptic?

A: No, Xaloptic T is not the same as a single-ingredient product. Xaloptic T is defined as a fixed-dose combination because it contains two distinct active ingredients: Latanoprost and Timolol. Single-ingredient products, such as Latanoprost alone, would only contain one active medicine.

Q: Is Xaloptic T considered a long-term treatment?

A: The medicine is indicated for treating conditions like glaucoma or ocular hypertension, which are chronic. Clinical research has examined its use for extended periods, suggesting a potential role as a maintenance therapy.

Q: Can I use Xaloptic T if I have another chronic health condition?

A: Regulatory documents state that use is absolutely prohibited (contraindicated) in individuals with specific severe pre-existing cardiac or respiratory diseases, such as asthma. Caution is also specifically advised for patients with conditions such as diabetes or significant hepatic (liver) or renal (kidney) impairment. Eligibility is determined by a healthcare provider based on an individual’s complete health status.

Q: Is Xaloptic T used globally, or only in certain countries?

A: The research evidence supporting the combination’s use includes data gathered from international Phase 3 studies. The drug is commonly reviewed by major regulatory bodies, which provides a basis for its use outside of a single country.

Q: Is Xaloptic T a beta-blocker?

A: Yes, it is a fixed combination that contains a medicine belonging to the beta-blocker class, which is Timolol. Xaloptic T also contains a second active ingredient, Latanoprost, a Prostaglandin Analog. This combination is structured to provide a dual action.

Q: What is the difference in how Xaloptic T and other similar medicines work?

A: Xaloptic T is a fixed combination that is designed to have a dual mechanism of action. The Latanoprost component works to increase fluid outflow, while the Timolol component works to reduce the rate at which fluid is produced. This combination is designed to work synergistically, aiming for an additive physiological modulation that reduces intraocular pressure.

Q: Are there known long-term risks associated with using Xaloptic T for many years?

A: One long-term ocular risk noted in official regulatory documents is the potential for increased iris pigmentation (eye color change). This change is described as being gradual and is often permanent, meaning it may not reverse even after stopping the treatment.

Q: Can I share my Xaloptic T with someone who has similar symptoms?

A: No. Regulatory guidance and official prescribing information state that prescription eye drop medication should not be shared with others. The medicine is prescribed based on an individual's specific diagnosis and health profile.

Q: Does the efficacy of Xaloptic T change over time?

A: Regulatory reviews of clinical research indicate that the reduction in intraocular pressure (IOP) that was achieved during the initial trials was generally maintained over treatment periods that lasted up to two years.

Q: Is Xaloptic T a steroid?

A: No. Official documents classify the two active ingredients in Xaloptic T as a Prostaglandin Analog and a Beta-Blocker. Neither component is classified as a steroid.

Q: How quickly does Xaloptic T start to work?

A: The onset of reduction in intraocular pressure is described in official product information as beginning approximately 3 to 4 hours after the eye drop is administered.

Q: When should I expect to see the full effect of Xaloptic T?

A: The maximum pressure-lowering effect is described in official regulatory information as being reached approximately 8 to 12 hours after the eye drop is applied.

Q: Does Xaloptic T cause any change in vision or blurriness?

A: Yes. Blurred vision is listed in regulatory labeling as one of the commonly reported adverse reactions from clinical trials. Any visual changes should be noted and reported to a healthcare provider.

Q: Are there any known drug-food interactions with Xaloptic T?

A: Regulatory information indicates that there are no specific drug-food interactions or warnings listed in the product's official documents.

Q: Does Xaloptic T contain a preservative?

A: Yes. This ophthalmic solution is formulated with a preservative, typically benzalkonium chloride (BAK). Regulatory documents note the presence of this preservative because it may be absorbed by soft contact lenses.

Q: Are there any reports of Xaloptic T causing mood changes?

A: Adverse reaction reports for the Timolol component can include generalized central nervous system (CNS) effects. However, specific mood changes are not consistently listed as common or uncommon effects in official product information.

Q: Do people typically experience tiredness when using Xaloptic T?

A: Regulatory information for medicines containing Timolol (the beta-blocker component) sometimes includes reports of fatigue or unusual tiredness/weakness as potential systemic effects.

Q: Why is Xaloptic T stored at a certain temperature?

A: The specific storage requirements, such as refrigerating unopened bottles between 2 C to 8 C (36 F to 46 F), are mandatory. These cold storage conditions are established by regulatory agencies to maintain the drug's stability and potency.

Q: Is it safe to drink alcohol while using Xaloptic T?

A: Official information generally indicates that it is unknown if drinking alcohol will affect the Latanoprost component, and there is no specific interaction warning listed for alcohol in the regulatory documents for this combination medicine.

Q: Does Xaloptic T have a black box warning in the US?

A: No. Regulatory documents indicate that this specific ophthalmic product does not carry a Black Box Warning (the FDA's most stringent warning).

Q: What does the 'T' stand for in Xaloptic T?

A: The 'T' is used to signify the fixed-dose combination and specifically indicates the presence of the second active ingredient, Timolol. This distinguishes it from the single-ingredient Latanoprost product.

Q: What ingredients are listed in Xaloptic T besides the active medicine?

A: Official regulatory labeling includes the complete composition of the solution. This list details the inactive ingredients, such as the preservative, typically benzalkonium chloride, which helps keep the solution sterile.

Q: Does Xaloptic T have any known effects on driving or operating machinery?

A: Yes, regulatory guidance includes a warning advising caution against driving or operating hazardous machinery immediately after application, due to the risk of temporary blurred vision or other visual disturbances.

Storage Requirements

Unopened bottles of Xaloptic T (latanoprost/timolol ophthalmic solution) must be stored under refrigeration at a temperature range of 2 C to 8 C (36 F to 46 F). The product must be protected from light and must not be frozen.

Once the bottle is opened for use, it may be stored at room temperature up to 25 C (77 F). The solution must be discarded six weeks (42 days) after opening, even if solution remains.

All medicine must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Xaloptic T must be disposed of according to local regulatory requirements. The product must not be poured down the drain or disposed of in general household waste.